Amedisys Stock Forecast, Price & News

-2.27 (-0.92 %)
(As of 06/23/2021 02:17 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume2,786 shs
Average Volume197,832 shs
Market Capitalization$7.94 billion
P/E Ratio40.24
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

Amedisys logo

About Amedisys

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.51 out of 5 stars

Medical Sector

579th out of 2,105 stocks

Home Health Care Services Industry

7th out of 12 stocks

Analyst Opinion: 2.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Amedisys (NASDAQ:AMED) Frequently Asked Questions

Is Amedisys a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys
or view top-rated stocks.

What stocks does MarketBeat like better than Amedisys?

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amedisys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 551,800 shares, an increase of 29.6% from the May 13th total of 425,700 shares. Based on an average trading volume of 190,200 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.7% of the shares of the company are sold short.
View Amedisys' Short Interest

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for Amedisys

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) issued its earnings results on Tuesday, April, 27th. The health services provider reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.43 by $0.11. The health services provider had revenue of $537.10 million for the quarter, compared to analysts' expectations of $544.89 million. Amedisys had a net margin of 9.53% and a trailing twelve-month return on equity of 28.53%. The company's quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.05 earnings per share.
View Amedisys' earnings history

How has Amedisys' stock been impacted by Coronavirus?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMED stock has increased by 43.4% and is now trading at $244.52.
View which stocks have been most impacted by COVID-19

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided earnings per share guidance of 6.850-7.070 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.370. The company issued revenue guidance of $2.30 billion-$2.34 billion, compared to the consensus revenue estimate of $2.30 billion.

What price target have analysts set for AMED?

11 equities research analysts have issued twelve-month price targets for Amedisys' stock. Their forecasts range from $245.00 to $350.00. On average, they expect Amedisys' stock price to reach $289.00 in the next year. This suggests a possible upside of 18.2% from the stock's current price.
View analysts' price targets for Amedisys
or view top-rated stocks among Wall Street analysts.

Who are Amedisys' key executives?

Amedisys' management team includes the following people:
  • Mr. Paul Berthold Kusserow, Chairman & CEO (Age 60, Pay $1.33M)
  • Mr. Christopher T. Gerard, Pres & COO (Age 54, Pay $1.34M)
  • Mr. Scott G. Ginn, Exec. VP & CFO (Age 52, Pay $1.22M)
  • Mr. David L. Kemmerly, Chief Legal & Gov. Affairs Officer (Age 58, Pay $851.77k)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 54, Pay $844.58k)
  • Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems
  • Mr. Michael P. North, Chief Information Officer (Age 56)
  • Ms. Denise Bohnert, Chief Compliance Officer (Age 43)
  • Kendra Kimmons, VP of Marketing & Communications
  • Mr. John Nugent, Chief Acquisitions Officer

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

297 employees have rated Amedisys CEO Paul B. Kusserow on Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.59%), Price T Rowe Associates Inc. MD (4.74%), JPMorgan Chase & Co. (3.59%), Riverbridge Partners LLC (2.79%), Ameriprise Financial Inc. (2.45%) and William Blair Investment Management LLC (2.30%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Dimensional Fund Advisors LP, Prudential Financial Inc., Great Lakes Advisors LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Arabesque Asset Management Ltd, and Putnam Investments LLC. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys
or view top insider-selling stocks.

Which major investors are buying Amedisys stock?

AMED stock was purchased by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Ameriprise Financial Inc., Riverbridge Partners LLC, BlackRock Inc., Artemis Investment Management LLP, Intrinsic Edge Capital Management LLC, Northern Trust Corp, and Principal Financial Group Inc.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys
or or view top insider-buying stocks.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $244.52.

How much money does Amedisys make?

Amedisys has a market capitalization of $7.96 billion and generates $2.07 billion in revenue each year. The health services provider earns $183.61 million in net income (profit) each year or $6.11 on an earnings per share basis.

How many employees does Amedisys have?

Amedisys employs 21,000 workers across the globe.

When was Amedisys founded?

Amedisys was founded in 1982.

What is Amedisys' official website?

The official website for Amedisys is

Where are Amedisys' headquarters?

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.